<SEC-DOCUMENT>0001095981-14-000005.txt : 20140402
<SEC-HEADER>0001095981-14-000005.hdr.sgml : 20140402
<ACCEPTANCE-DATETIME>20140402160626
ACCESSION NUMBER:		0001095981-14-000005
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140402
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140402
DATE AS OF CHANGE:		20140402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		14738052

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cytori8k_040214.htm
<DESCRIPTION>CYTORI THERAPEUTICS FORM 8-K
<TEXT>
<html>
<head>
    <title>cytori8k_040214.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Form 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Report</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(Date of earliest event reported):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160; April 2, 2014</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-34375</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 40.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">33-0827593</font></div>
</td>
</tr><tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File</font></div>

<div style="TEXT-INDENT: -54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 40.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3020 Callan Road, San Diego, California 92121</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices) (Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(858) 458-0900</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">n/a</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="FONT-STYLE: italic; DISPLAY: inline">see</font> General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="hangingindent"><!--EFPlaceholder--></a><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="&#61556;&#61537;&#61538;&#61490;"><!--efplaceholder--></a>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9633;</font></font></div>
</div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5.02&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 2, 2014, Cytori Therapeutics, Inc. (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;) announced that Christopher J. Calhoun, the Company&#8217;s Chief Executive Officer, is retiring from the position of Chief Executive Officer effective immediately.&#160;&#160;Mr. Calhoun has agreed to serve as Managing Director for a transition period beginning April 2, 2014 through July 1, 2014 to facilitate the orderly transfer of his responsibilities.&#160;&#160;Effective July 1, 2014, Mr. Calhoun will retire as a director and employee of the Company.&#160;&#160;There were no disagreements with the Company that led to Mr. Calhoun&#8217;s decision to retire from the Board of Directors (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Board</font>&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also on April 2, 2014, the Board appointed Marc H. Hedrick, M.D., the Company&#8217;s President and Director, as&#160;Chief Executive Officer, effective immediately.&#160;&#160;Detailed biographical information about Dr. Hedrick and his current compensation is available in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Securities and Exchange Commission (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">SEC</font>&#8221;) on March 14, 2014, and in the Company&#8217;s Definitive Proxy Statement on Schedule 14A, filed with the SEC on July 19, 2013, which information is incorporated herein by reference.&#160;&#160;Dr. Hedrick will not receive additional compensation for his service as Chief Executive Officer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company issued a press release announcing these senior management changes. A copy of the press release is filed hereto as Exhibit 99.1 and incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is no arrangement or understanding between Dr. Hedrick and any other person pursuant to which he was selected as an officer of the Company. Dr. Hedrick has no family relationship (within the meaning of Item 401(d) of Regulation S-K) with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. There has been no transaction since the beginning of the Company&#8217;s last fiscal year, and there is no currently proposed transaction, in excess of $120,000 in which the Company is or was a participant and in which Dr. Hedrick or any of his immediate family members (within the meaning of Item 404 of Regulation S-K) had or will have a direct or indirect material interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01&#160;&#160;Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated April 2, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Date:&#160; April 2, 2014</font></div>
</td>
<td align="left" valign="middle" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;By:&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="36%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated April 2, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1 CYTORI PRESS RELEASE
<TEXT>
<html>
<head>
    <title>exhibit991_pressrelease.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div><br>
<img src="cytori_logo.jpg" alt="CYTORI LOGO"></div>

<div><br>
&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS CONTACT</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Megan McCormick</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">+1.858.875.5279</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">mmccormick@cytori.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Cytori Announces Senior Management Changes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SAN DIEGO, April 2, 2014 &#8211; Cytori Therapeutics (NASDAQ: CYTX) today announced that Christopher Calhoun, Chief Executive Officer and Director of Cytori Therapeutics, is retiring from the position of CEO of the Company, effective immediately. The Board of Directors has named Dr. Marc Hedrick to the position of CEO, in addition to his current responsibilities as President and Director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During a transition period, Mr. Calhoun will remain a Director on Cytori&#8217;s Board and will assume the position of Managing Director. As Managing Director, he will focus principally on Cytori&#8217;s international business development efforts until his retirement from the Company on July 1,<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are extremely grateful to Chris for his efforts over the past 18 years to build Cytori into a world leader in adipose-derived cell therapy,&#8221; said Mr. David Rickey, Chairman of the Board of Cytori. &#8220;Mr. Calhoun founded the Company in 1996 and had the strategic vision in 2002 to acquire StemSource, Inc., led by Dr. Hedrick, enabling the development of our core cell therapy technology. Dr. Hedrick has served as President since 2004 and has overseen research, development, sales and marketing groups.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Hedrick is a former general, vascular and plastic surgeon with an MD from University of Texas Southwestern Medical School and an MBA from University of California, Los Angeles. He and his team at UCLA discovered stem and regenerative cells in human adipose tissue.&#160;&#160;&#8220;This is a tremendous opportunity to guide Cytori and to advance the strategic vision to become the premier cell therapy company,&#8221; said Dr. Hedrick. &#8220;I am committed to the Company, its shareholders and employees and look forward to the day that our important new therapies will benefit patients around the world and reward those who have put their trust in us.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;I am passionate about Cytori and its technology and will continue to be dedicated to the Company&#8217;s mission and success,&#8221; said Mr. Calhoun.&#160;&#8220;It has been an honor to have worked with so many talented and dedicated colleagues, partners and physicians around the world and to have been part of making a positive difference for patients.&#160; I have known and worked with Dr. Hedrick for more than 12 years and have full confidence in his ability to lead the Company forward.&#160; He will have my complete support during this transition and beyond.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Cytori Therapeutics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple &#8220;ischemic&#8221; conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori&#8217;s proprietary technologies and products, including the Celution&#174; System product family. <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cytori.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">###</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cytori_logo.jpg
<DESCRIPTION>CYTORI LOGO
<TEXT>
begin 644 cytori_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$D`
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`:.E'0'->`?MA?\`!0CP7^Q]I;)J32:UKTBYATJU8+)T
MR#(YX1?P)]J_/3XV_P#!?GXH-INH?V;X-\*:5I5Q$8P)UNI;E5;C<LH=$#8/
M]ROHLLX5S'&P]K2A:/=M*_I?5GQF=<>9/EE?ZM7J7J=HINWK;1?-GUM^V1^W
M3XJO_%\GPY^#MJ]_KTC>3<:C$OF^43QMC[#_`'OR_AW?'G[4?_!';X\>-?A?
MKGCWQ)XXT[5-4TVQEU&XT^\O[B6X\J-"\BA]ICWX!(%?0O\`P0F^*OA_]H7P
M[XL\1-8_9?%^FSQI>H[B78LWF8DC;`X.QATX^85T_P#P5J_;VMO`?PVU'X9^
M"6_MKQIXH1K"<6K;UM(VX=#CJ2.&']W<.OW>R$:^#Q:P6'@E*-N9M7[-OTL)
MU,-F.">.J3<HRORI-K7:UN]]&>!?\&Z_[4/CSQ=XR\5?#OQ!K&IZYH>F6)O;
M-;V=[A],=71617;)5#O^[TS7ZTK7Q-_P1E_X)_WO['OP8NM<\30^7XR\8*LM
MQ$X(>SA)W;#GD.QP6'^PO0[J^V`,CKWKQ<ZK4ZF+E*E:WEU?5GN9#1JTL'&%
M:]_/HNB'44#I17EGL!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`#=V*\U_:K^-"_`?X,:IKBX-YM^SV8(SF9E8@_@%)_"O2CTKP?\`X*#>
M`KGQW\#0ENI?[#?13R#_`&!G)_I^-=F6TZ<\5"%7X6U<\W-JE6&$J2H_%9V]
M3P+]AW]CJQ^.NL7GQ*^(4)URXGN&-O;W3%T9R=Q9L_>`SGW_`.^MU[_@N/X\
M\$_#S]A;4/!]]#ID.H>(KBVCTBT5$5H#%.DDDJH,;0$#)D?\]/[NZLOXZ?\`
M!1O0?^":W[*5I%=6)U;Q9J#.NC:?RL4I*@!Y,<[!CHOWO]GYBOS!^R3_`,$Y
M_BK_`,%5OB3'\9OC]JVHZ;X6O'$MCIZCRY[Z)6XCB3I##_M8^G?;]I!R>-_M
M#&SY:--^ZN]MDDOQ/SG%4(++WE674^>O55I2MMS+5MOK;;730Z'_`((P?!#Q
M1X6^!'B77=/U#^R&\?7$6F6#2-Y7F10>9NES_=+/M'^ZU?>?[./_``3W\(_!
M37V\3:E&OB#Q<[>9]MNEWK;-G.8P>X_O5YC^UG;:;\`M>\*>&?#-O!I>FVZV
M\5I90?+'`J%%`_*OL3P_=R7NA6,TW^MF@C=_]XJ":\7/LTJXFH\3'W54Z+>R
MLE=^A]7PSDM+`X6&#E[TJ:W\VVVTO5FE10.*,YKYD^M"BC-&:`"BC-!-`#0#
MGTHQC_\`50HKX=_X*H?\%'O'G[#_`(]\*Z3X3TOPG?6^N6$MW.^K6UQ,ZLC[
M0$\J:,8QZBM\+AJE>HJ5):LY<9C*>&INK5V7;4^XR*0+Q7F/['_QBU3X_P#[
M-'@_QEK,%C;ZIX@T];NYBLT=($<EAA`[,0O'=C7IY-95*;A)PENM/N-J-2-2
M"G'9BT445)H%%&:*`"BC-%`!1110`4444`%%%%`'(_%KXO>'?@?X)NO$7BC4
MK?2M)LUR\TK@;B>BJ.K,>P%?)7A+]MGQ7^W1XYFT?X?Z+<V/A*"7;/>SQ?-.
M@/WF)X4>W_H7RU\>?M(_&3Q%_P`%0OV_=,\!Z7J3Q>%8M3?3],@C),*6Z$F:
M[*Y&YV1&D_W=J]J_6;X5_"CPI^R_\*H='T>"UT?1])AW2S/C<^!S)(W&YC_]
M85]IB\KH9/AZ?MX\V(J*Z72*Z7ZM_J?F&5\08KB'&U?JLN3"4G9RZS?D]DDM
M?1GX/_\`!0GXR6]S_P`%7-/TGX@221^%O".J0Z;<A5+K!#&Y3S4&,XX\SZLU
M?LMXK_X**_!#X4^`K>;2?&WA?6;>&W1+*PT2\BNF*!`$0",D(`,=>@[5\#_M
M$?L"^$?^"K'[<.H:EIUSJF@,IQ>:G9*KI+%&>'DC88W;>.".=O\`>KZ5_9U_
MX(+?"WX,:E#>:UK7B#QI-;MN6&Z*6ML2/[R)EC_WU6F=?5.2E#$MJ<8IN*7>
MV_9G7P]]<=6O4PT5*$I-*3?;33NK6*7[.7AW7OV\OCY)X^UVSFL_"NGR[K>.
M1>)<=$'U'Z<_W=WWR!Q6=X>\-V/A+2(-/TRSM[&QM5V100($2,>P%4_B+XRA
M^'W@#7->N%:2'1=/GOY%'5EBC:0C\A7R6*Q+KS2BK):)'VV%PZP\&YN[>K9\
MV?MV_P#!5?P=^Q;JO_"/06,WBSQL$65],MY_(AL4891IYBK;25Y"*K-CKM#*
M6^.E_P"#@WXE'6C(W@OP.VF$Y\A?M0G^]_SU\W'W?]C_`.)KPO\`8N^"-U_P
M4+_;:6U\5WUS/#JTUQK_`(@N(VVR2Q*VYT0]MSND?^P&_P!FOUZ_X=S?`T^#
MO[#_`.%6^"Q9^7Y7F?8%^V8QC_CZ_P!?N_VM^:]^O2R_`<M*M!SFU=OM^)\W
MAZV8YBY5J$U""=DN_P"!PO["_P#P5+\$_MIWG]B_99O"?C2.,R?V3=3B9+M%
M&6:WEPOF8')4JK]]I4;JX;_@HQ_P4^\:?L-?&>QT*U\&:+K&B:OIR7]G>W%S
M+&[D,4EC(7C<I&?HZUZ/^R+_`,$N_AS^R'X]U?Q-HZ76LZQ>3N-.GU(B1M&M
MV_Y8Q?[?W@93\Y7`_O;N$_X+A?L]?\+;_9)7Q19P^9JWP_NA?A@N6:TEQ'<+
M^'[J0_\`7*O/H_498Z,8)\DM->C?8]&O]?CE\I3:52.MUV7_``#Z7_9J^-5G
M^T9\!/"GCBQC2&/Q%I\=U)"K;Q;3?=EBSQGRY%=,_P"S7F7_``4>_;@_X88^
M#^FZY9Z99ZQK6L:DEA9V=Q*8D9`C/+(2O.U54#_>D6OG[_@W^^/?_"3_``;\
M4?#NZF9KKPO?#4K%2W_+K<<.BC^ZDR,3_P!=Q7SO_P`%S?CC)\5?VN;/P?92
M27%GX%L8[3R4R^Z]N-LLN,=]A@7ZK6V&RI/,98>:]V-V_3I^AEB<XDLLCB(/
MWY))>O4^_O\`@FS^V-XH_;:^&>N>*M=\-Z;X=T^SU`6&GBUEDD-RRINE8[_X
M1O0#'^U7Y=_\%1/VMM2_:C_:#NK2_P!'L]+7P'=7VAV[6\CNUTB7+C>^[[K?
M)VK]@_V+?@)'^S3^S#X+\'&-4O-,T]'U#;SNO)/WL[9[_O68#VQ7Y[?\'#B[
M?C)\/??1K@_^1JZ,FJT?[2:IQT=^7?1+_,YL\HU_[,BZD]5;FT6K;_1G6?\`
M!(O_`(*0:UXT\4^!?@C)X;TN+2[#3;B)=3CN)#<$0Q22@E3QR1BOTPD98P69
M@JKR2>F*\+_X)EC_`(P+^%_R_P#,&CY_X$U8O_!6?XD7OPN_8-\=7NFS/;WF
MHPP:4DBG#*EQ.D<N/K$SBO,QD8U\=[.G'EO*V]];V;_X!ZN!E/#8'VM67-:-
M]K:6V_X)X#^UA_P7@T7X;>+;S0/AMH5MXMET^0Q3ZQ>7!33W<<'R43YI4_V]
MR+Z;A\U>8_#3_@X3\76VMQ?\)AX#\.WVFNV)#H\\]K-$I/WAYK2!B/[O&?5:
MY'_@BU^Q%X5_:;\4^*O$_C738]:TGPO]GM[+3YMWV:YN)=[,\@!&\(J+\AX/
MF\U]=?\`!1#_`()K?#'Q?^S1XJUOPSX/T'PGXD\+Z9/JMG<:/91V:S>0C2/#
M)'$%1]Z*5!(R#MYXKV:T,LP]98.<&WHG+S?S/#HU,UQ%%XR$TEJU'R7R_4^E
M/V?OV@_"_P"T[\,;#Q=X1U%;_2;[*L#\LUI*H&^&5,G9(F1D?0C*L"8?VK?C
M/=?L]?L[>+/&ME8PZC=>'+!KN.VF<I',00-I(Y[U^;/_``;Z?$Z\T[X[>,O!
M[7#?V;JNB?VJL3-QY]O/'%N`]2DYS_N?[-?>?_!3+_DPCXH_]@9__0EKQ\5E
M\:&.6'>L6U]S:/:P>93Q&7NNM))/[T?(7P\_X."$E\)>(KSQ3X+MX]6M5@71
MK#3KF3;?._F>8997!$:+MCZ!F^;I_=X73?\`@X2^(:>)UEN_`O@ZXT<M_P`>
ML$MS%<XST\XNR;O^V=>>_P#!'#]C_P`-_M5_'36KKQ?9#5-`\(V*71L&<K%=
MW$DFV(28()1520X_B^7/&Y6_4:?_`()_?!D>--!U^W^&_A72]4\,W"W5A+IU
MDMFJR#[K21Q;4E(;##>&PRJ:]?'?V;A*LJ+I\SMWT6FG7[SQ<O6:8RC&K&JH
MJ_S>NO0]$^%?C2\^(7PZT77;S1-2\-W6J64=U+I=_L^T6)89\M]I(S^OJ%.5
MKX;_`&6/^"R7B?\`:`_:RT'X=WG@O0]/LM6OKBT>\@NI7EC$<<CA@#QSY=?H
M2X_=D>@K\+/^":W_`"D]\&_]AB^_])[FO.RK"TJU*M.4?A5UOIN>IG&+K4*M
M"$)6YG9[:['[K`Y%%`X%%>&?1!1110!^$?C']D#X\?L%_M&+KWAWPQXBO)=!
MO7GTS6]+TU[ZTNHL,-S[`ZIN0L&CDVM7T)X8M_VNOV_+J'3?$5KJ'A/PN)1Y
M\EU8'2H64<$[&`DEY^M?JHT88<JI^M"K@_*%7Z5]UB..JM:*E4H0=6*LIM7:
M]%WOJ?E.#\*Z&%FZ='%5(T&[N"=D_)OJK:/2[[GE?[+/[+6A_LN>!DTO3&DO
M+R<*UY>RC#SN!UQ_"/:O50/E]Z4+D4-P:^*Q&(J5JCJU7>3W9^FX3"4L-2C0
MH+EC%62'$9%<#^TSX/G^(/[.?CWP_:JTEQKGAW4+")4^\SRVTD8`X/.6KOL\
M4TG*X-9PERR4NVIK4IJ<7'N?BC_P0Z^)&G>`/VY(;/4)5A_X2K1+K2+9GX4S
M&2&X5<^I^SX'OQ7[79S7Y"_\%(?^"4GC3X6?%?4?'GPMTJ^USPWJEX=0^Q:4
MKOJ.B7#-YC[(T&]H]_*-'\R=#MVJS>.M_P`%'?VF'TMO"/\`PFWBD2M'Y)@_
MLV)=2QG;Q-Y7V@-N_BW[J^OQV`CF4HXG#S6J2:>ZL?%X#,IY9&6%Q%-Z-V:Z
MW/W,TW7++5Y[A;.ZM[I[.8V]QY4@D\F10"4?!X<!AP>:A\9^$[#Q_P"$M4T/
M5(%N=-UBSELKJ(])894*.OXJ37YS_P#!&W]DOXT_#GXD7WC;Q1=:QX6\)ZM%
M(UWH^I9:Y\03./DE>)_FCVL=WFMAV^[]UFK]+LY%?-8S#QP]9PIR4K=5W/J,
M#B98JCSU(.-^C['X<_LG?$:3_@FA_P`%$M2L?$LUQ#I.CW%]H.K.L9W7-LW,
M,H`_A+I;R_[M/_X)U_#Z_P#VV?\`@HS9Z_K<9N([?4KCQAK&<E`4F\R-.>QN
M'B7']RO4?^"_WP2L_!OQW\+^-K5H8W\9:?);7L0(#M/9^6JS$9RV8YHD_P"V
M0KW3_@@3^S\W@OX":]\0+R$K>>,[W[+9,5_Y<[8E=P_WIC*#_P!<EKZ_$8N"
MP+QJ^.<5'YW:_P`_N/B\/@JCQZP3^"$G*WE9/_+[V??P'/TK\G_^#AW_`)+)
M\//^P-<?^CJ_6+I7P'_P6V_8S\4_M!>$/#'B_P`&Z7=:YJ'A47%MJ&G6L?F7
M<]O(49)(D'+^6Z'*+EOWG`X-?-Y'6A3QD95'9:K[T?4<049U<%*%-7>C^YH^
MA/\`@F7S^P5\+O\`L"I_Z$U>?_\`!;'0GUC_`()_>)9T5V_LV_L+IMOH;I(N
M?^_E?+/_``2)^.?QNT[X[^$_AKKTGB*S^'=E:WRBQO-#2)(2L4DBK]H:(2KB
M3H-_M7Z8?&3X5Z7\</A=KWA'6XWDTOQ!8R65QL.UT#C`=3_"ZG#+[@5IBJ;P
MF/52337-S:=F_P`R,'+ZYESIQ33Y>77NE;[CX!_X-X/%]E)X4^)7A\R*FH1W
MEGJ`C+<RQ,DD98#V9.?]Y:^U?VUO%ECX(_9%^)6I:A.EO:P^&[^,%FV[GD@>
M.-!_M-(Z*/=A7X__`!@_9*^-_P#P3=^,,NJZ"GB"&UM6=-/\3:+!(]M=0L>%
MEV[@A/\`%%+WZ;E^:L+Q?\?/VA/^"@7V/P[>7GBKQW"LP>.PT[3$BMO,7H\B
MV\:1_+G[\G2O8Q64QQ6*^MPJ+D=FW?:UO\NIXF%S>>%POU*=-\Z325M[GLG_
M``0&T2:__;+UN\4,L-CX6NBQV\9>YM5"_C\Q_P"`U^C'_!308_8*^*/_`&!G
M_P#0EK@_^"6/_!/^;]BOX7W]YX@:&;QQXK\M]2$3!X].C0$QVR,,AF!=B[CA
MC@?,$5F]`_X*/Z5=:U^PU\2K.SMY[RZN-'=8H((S))*=Z\!1DFO*QV*A7S*-
M2#NDXJ_>S1ZV7X.=#*Y0FK2:;MVNCXF_X-U_^1S^*G_7IIW_`*'<5^IG2OS&
M_P"#?KP-K?A'Q?\`$]M6T?5M+6XM=.$9N[.2W$I#W&<;@,XS7Z<9R166?R3Q
MLFO+\D;\.1<<#!/S_,'Y5OI7X5_\$U?^4GW@W_L,WW_I/<U^ZC\(:_$C_@G3
M\+O$VB_\%*?!U]>>'=>L[&/5[UFN)M/E2-0;>Y`)<J%[UU9')*AB$W]G_,Y.
M((MU\.TOM?JC]N:***^=/J`HHHH`****`"BBB@`HHHH`,9I-B_W1^5+10%D-
MVUY[^TI^T1X?_97^$M_XT\31ZA)H^FR11S+91"6;,D@1,*64?>8=Z]"DKY)_
MX+6?\H^/%O\`U^Z=_P"EL5=&"HQJUX4I;2:3./'UI4</*I#=*Y^</[?'[5-U
M_P`%(?VJ-#B\)Z9J4>FQK%HF@65SCS[F623F5D4LJF1W4=3\BK7[1_`KX3V7
MP+^#?AGP?I^UK7P[IT-BKA=OG,B`/(1ZNVYC[M7XJ_\`!(K_`)2&>`?^NMU_
MZ0M7[MQ=*]_B2*H>SPM/X4K_`-?UU/G>%FZZJ8RIK*3^[T_KH+GI28YJO#_K
M/PI'^ZOT'\C7RW=GUE^A:"X-*1FJDO\`J&^H_E3_`.-/I_A1S:LKH6",T@11
M_"/RJ$=OK42?Q?\``J(ZL'%7+1^8TI.[BH/XV_WA_2F?\MW^J_SH4M;>0F];
M%H+Z4N=U4Y/]9^?\Q3A_K!_NK_.J&6!_=HVJ#52?_7O_`+J_S-/?JWX_TI)@
LT6J"N:JO_K)/]W^M*_\`K%^M)LGF+"?=I%&#41^\OX_SJ+_EK_P(U11__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
